anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Outcomes of unresectable biliary tract cancer (BTC) with varying extents of liver involvement remain unclear. We evaluated characteristics and outcomes of BTC patients with liver metastases who underwent chemotherapy.
METHODS: We retrospectively reviewed consecutive BTC patients with synchronous or metachronous intrahepatic metastases who started first-line chemotherapy at our institution between January 2016 and December 2021.
RESULTS: Ninety-six patients were included, of which 57 only had liver metastases and 39 had multiorgan involvement. The liver only group had longer median overall survival (OS) (11.8 vs. 7.4 months, P = 0.006) and median progression-free survival (PFS) (4.1 vs. 2.7 months, P = 0.035) than the multiorgan group. Patients with oligometastases (defined as no more than three liver metastases) achieved longer OS than those with polymetastases (four or more liver metastases) in the entire cohort. Within the liver only group, there were no significant differences in OS or PFS between the oligometastasis and polymetastasis groups. Patients who underwent subsequent surgery had significantly longer median OS than those who did not (44.4 vs. 7.7 months, P < 0.001). Age ≥ 75 years, liver-only metastasis, modified Glasgow prognostic score ≥ 1 carcinoembryonic antigen ≥ 5 μg/L, and subsequent surgery were independent predictors of OS. Liver oligometastasis was only a significant predictor of longer OS in univariate Cox analysis.
CONCLUSIONS: Outcomes in BTC patients with metastases limited to the liver, particularly those with oligometastasis, were more favorable than those with multiorgan metastases. Selected cases, generally with liver oligometastases, may achieve prolonged OS through subsequent surgery.
A stable piroxicam injection compsn.contains piroxicam as  an effective ingredient, 1.1 - 1.2 mole  of  L-arginine  or  L-lysine (relative to 1 mole piroxicam) as a solubilizing agent, 15-25  W/V % of  propylene  glycol  mixture  and  1-2  W/V  %  of  polyvinyl pyrrolidone. Also claimed is  the  prepn.  of  the  compsn.  which comprises  dissolving  piroxicam  with  L-arginine,  L-lysine  and propylene glycol in distilled  water  for  injection,  and  adding polyvinyl  pyrrolidone  into  the  obtd.  soln  as  a  stabilizer. Piroxicam is useful as a nonsteroidal antiphlogistic analgesic.
<P>PROBLEM TO BE SOLVED: To provide a dentifrice composition having high stability of an ascorbic acid phosphoric ester salt and excellent prophylactic effects on gingivitis, improving irritation with high pH during or after toothbrushing, bitterness derived from the ascorbic acid phosphoric ester salt or astringency derived from a siliceous polishing agent and having a good feeling of use.  <P>SOLUTION: The dentifrice composition comprises (A) the ascorbic acid phosphoric ester salt, (B) trimethylglycine, (C) the siliceous polishing agent and (D) an alkaline agent. The formulation ratio of the (B) ingredient/(C) ingredient is 0.02-3.0 expressed in terms of mass ratio. The initial pH of the composition and pH at 25°C after preserving for 1 month at 25°C is 8.0-9.5. Furthermore, the dentifrice composition contains (E) at least one kind of acidic mucopolysaccharides.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Small extracellular vesicles (sEVs) are cargo-carrying cellular nano-vesicles that have been explored for developing organic drug delivery modalities (DVM), an alternative to synthetic liposomes. However, scaled-up production of sEVs is a notable challenge in bringing sEV-based DVMs from the bench to the clinic. Ultracentrifugation is the most accepted isolation approach, but the cumbersome logistical issues and aftereffects of intense 'g' force hinder their applicability. In this study, we developed a new amenable isolation strategy for sEVs using a combinatorial treatment of calcium chloride and polyethylene glycol (PEG). An equivalent volume of cell culture medium from growing lung cancer A549 and H1299 cells was incubated overnight at 4 °C with different formulations (0.1 M CaCl2, 8% PEG, 12% PEG, 0.1 M CaCl2 + 8% PEG, and 0.1 M CaCl2 + 12% PEG) and centrifuged at 4000g to purify the precipitated sEVs as a pellet. Next, the extra CaCl2 was chelated out and the buffer was exchanged with PBS. The sEV number and protein content were assessed using the NTA (nanoparticle tracking analysis) and the BCA assay, respectively. Finally, transmission electron microscopy (TEM) was used to visualize the sEVs. The data from the present study demonstrated that the combination of 8% PEG and 0.1 M CaCl2 produced comparable numbers of sEVs with the ultracentrifugation technique. The sEV characteristics and structural integrity also remained intact, as evident from the TEM images and western blot assay. Thus, here we report an efficient technique for sEV isolation that can be easily scaled up.
<P>PROBLEM TO BE SOLVED: To provide a method for identifying compounds altering internalization of a GPCR (G protein-coupled receptor).  <P>SOLUTION: An agonist-independent method for screening for compounds altering the desensitization of the GPCR is provided. A GRK (G protein-coupled receptor kinase) desensitizing the GPCR in the absence of an agonist and a cell line modifying the GRK are included. The method for identifying whether or not the GPCR is expressed with a plasmic membrane and the GPCR has an affinity for arrestin is provided. Furthermore, a modified GPCR having an increased affinity for the arrestin is included. The modified GPCR is useful for methods for screening for the compounds altering the desensitization comprising the agonist-independent method and the agonist-dependent method described in the specification.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
The invention belongs to the technical field of cosmetics, and discloses a bletilla striata skin-beautifying repairing skin-care preparation as well as a preparation method and application thereof. The preparation uses bletilla striata root water and bletilla striata root extract as a moisturizing agent and a skin conditioner, and is used for conditioning skin, moisturizing, whitening and removing freckles; adding the humectant again for resisting bacteria and further improving moisture retention; the skin conditioner is used for resisting oxidation and relieving allergy; mixing antioxidant and solvent, and has effects of moistening and conditioning skin, resisting aging, resisting oxidation, removing acne, relieving allergy, relieving inflammation, whitening skin, removing speckle, resisting bacteria, astringing follicular orifice, improving skin crystal permeability, moistening skin, supplementing water, making skin bright, white, smooth and fine. The thickening agent, the regulator and the chelating agent are added, so that the emulsification degree among the raw materials is improved, and the stability is improved. The product is free of any essence and antiseptic, and is suitable for all people. The process is simple, the operation equipment is few, the requirement on the operator is not high, and the cost is low. The preparation is safe and reliable, has no toxic and side effects, and is suitable for mass production in factories.
Enrollment will begin and will end once 30 eligible subjects have been identified. Anticipated duration is one year. Participants will enroll in one of the 4 different training series. Each series will have 3 dates they must attend. Once enrolled and consent is documented, eligible subject's will participate in the study for approximately three months. Participants will be expected to attend 3 training sessions over a 4 week period, each are up to 3 hours in length. There will be a follow-up post-survey one month after the last training and an optional phone interview that will occur 2 months after the final training. Participants will be compensated for their time with a $50 gift card once the final post-survey has been received. The gift card will be mailed to the family. Data analysis will begin once all trainings have been completed. Investigators anticipate completing the study, including primary analyses, within two years from the date recruitment begins.
The invention refers to genetic engineering, can be used in biotechnology, medicine, agriculture for creating gene therapy drugs. A gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying a therapeutic gene selected from the group of IFNB1, IFNA14, IFNA2, IL12A, IL12B genes to increase the expression level of the gene in humans and animals. The gene therapy DNA vector VTvaf17 IFNB1, or VTvaf17-IFNA14, or VTvaf17-IFNA2, or VTvaf17-IL12A, or VTvaf17-IL12B has a nucleotide sequence SEQ ID No. 1-5, respectively. The vector due to the limited size efficiently penetrates into cells and express the gene, does not contain nucleotide sequences of viral origin, antibiotic resistance genes, providing its safe use for genetic therapy in humans and animals. A method of production of the vector, a method of use of the vector, a Escherichia coli strain SCSI 10- AF carrying the vector, a method of industrial production of the vector are proposed.
INTRODUCTION: The Brazilian Dialysis Survey (BDS) is an annual national survey about patients on chronic dialysis that contributes to health policies.
OBJECTIVE: To report the 2022 epidemiological data from the BDS of the Brazilian Society of Nephrology (BSN).
METHODS: A survey was carried out in Brazilian chronic dialysis centers using an online questionnaire that included clinical and epidemiological aspects of patients on chronic dialysis, dialysis therapy data, and dialysis center characteristics.
RESULTS: Overall, 28% (n = 243) of the centers answered the questionnaire. In July 2022, the estimated total number of patients on dialysis was 153,831. The estimated prevalence and incidence rates of patients per million population (pmp) were 758 and 214, respectively. Of the prevalent patients, 95.3% were on hemodialysis (HD, 4.6% of these on hemodiafiltration) and 4.7% on peritoneal dialysis (PD). Only 1.3% of patients were not vaccinated against COVID-19. The prevalence of anemia (Hb < 10g/dL) was 27% and hyperphosphatemia (P > 5.5mg/dL) reached 30%. The estimated overall crude annual mortality rate was 17.1%.
CONCLUSIONS: The absolute number and prevalence rate of patients on chronic dialysis continue to increase. A growing number of patients were receiving hemodiafiltration. The mortality rate decreased, probably due to the end of COVID-19 pandemic. The conclusions were drawn in the context of relatively low voluntary participation, which imposed methodological limitations on our estimates.
PROBLEM TO BE SOLVED: To obtain the subject new compound having potent proliferation- suppressive effect against mouse and human oncocytes, thus as an antineoplastic agent for treating cancers in the medicinal field. SOLUTION: This new compound is expressed by the formula (R is COOCH3 or CH2 OH), being obtained by the following process: microorganisms having ability to produce this compound [e.g. Streptomyces sp. A52440] or its variant is inoculated into a nutrient-contg. medium and cultured by e.g. aerobic liquid culture method (in particular, shaking culture or deep aerobic agitation culture) at pH4-8 at 16-38 deg.C; the resultant culture fluid is filtered to obtain microbes, which are then subjected to extraction with an organic solvent, the resultant crude extract is partitioned with a water-ethyl, acetate system followed by distilling off the ethyl acetate, and the resultant residue is subjected to silica gel chromatography.
PURPOSE:To obtain the titled agent having strong proliferation suppressing effect against tumor cell, excellent differentiation inducing effect to recover a tumor cell into normal cell, low toxicity and high stability in the body, capable of being administered at a high dose and effective especially against neuroblastoma, by using alpha-carotene as an active component. CONSTITUTION:The objective antitumor agent contains alpha-carotene as an active component. The alpha-carotene may be synthetic one or of natural origin. The natural carotene is especially preferably obtained by the extraction, concentration and purification of palm oil. The obtained carotene is a mixture of alpha, beta, etc., and the natural carotene can be easily absorbed in the body when administered to human body. An agent containing isolated alpha-carotene as an active component has excellent proliferation suppressing effect against tumor cell and differentiation inducing action compared with an agent containing a mixture of carotenes. It is administered singly or in combination with other drug components in the form of oral drug, suppository, injection, etc.
PURPOSE OF REVIEW: The purpose of this review is to critically evaluate the effects of vitamin D on muscle mass and physical/muscle function in middle-aged and older adults, based on recent human studies, including cross-sectional, observational, and intervention studies. Vitamin D, beyond its well established role in bone health, has shown potential in influencing muscle physiology, making it a nutrient of interest in the context of sarcopenia and related chronic conditions.
RECENT FINDINGS: The review states how vitamin D affects muscle function, emphasizing its role in muscle cell proliferation, differentiation, and key signaling pathways. Additionally, the review of recent human studies revealed an inconsistent relationship between vitamin D and sarcopenia and related indices, with mixed results regarding muscle mass and strength. Variability in supplementation dose, duration, and baseline 25-hydroxyvitamin D levels may contribute to these inconsistencies.
SUMMARY: While animal studies indicate vitamin D's effectiveness in muscle growth, cross-sectional, observational, and intervention studies do not show clear benefits of maintaining efficient vitamin D levels on muscle mass or function in humans. Although vitamin D impacts muscle health, it is insufficient alone, emphasizing the need for a multifaceted approach to sarcopenia prevention and management.
PURPOSE:The titled treating agent, obtained by uniformly dispersing and placing an adhesive or self-adhesive on the surface of a support made of a flexible film, sheet, etc., as a material in the form of fine dots or fine lines at a constant space factor and capable of giving damage to an extent of no irritation. CONSTITUTION:A skin treating agent for percutaneous medication, obtained by uniformly dispersing and placing an adhesive, e.g. cyanoacrylate based adhesive, etc., or self-adhesive, e.g. rubber based or acrylic copolymer based self-adhesive, etc., on the surface of a flexible sheet or film which is normally used as a support for pressure-sensitive adhesive, e.g. plastic, cellophane, paper, vinyl resin, etc., and adjusting the effective bonding area to 0.001-5% based on the total area of the support. The above-mentioned adhesive can also be used by sealing in microcapsules of several mum - tens of mum size and a curing agent contained in microcapsules of several mum - tens of mum size can be further dispersed in the adhesive.
The present invention relates to an in vivo method of monitoring an analyte in a subject. This method involves providing an expression vector that encodes a biosensor molecule, the biosensor molecule comprising an analyte binding domain and a signal domain. The biosensor molecule produces a signal from the signal domain upon binding of the analyte by the analyte binding domain. The signal is detectable by a non-invasive means. The expression vector is introduced locally into in vivo cells of a subject under conditions effective to express the biosensor molecule in the cells. The signal from the expressed biosensor molecule is detected by a non-invasive means, thereby monitoring the analyte in the subject in vivo.
HO170 DLBCL-ANTICIPATE: "Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell lymphoma" is a national randomized controlled trial that will be conducted across 25 Dutch hospitals. This study will include adult patients with DLBCL in which first-line treatment with 6 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is planned (cumulative doxorubicin dose 300 mg/m2). In this trial, we have chosen to include patients with a normal cardiac function before chemotherapy because cardiac dysfunction is a contra-indication for administration of anthracyclines. A total of 324 DLBCL patients will prior to treatment be randomized in a 1:1 ratio to either (1) intravenous dexrazoxane administration in a 10:1 dexrazoxane:doxorubicin ratio prior to each doxorubicin infusion or (2) no cardioprotective treatment (current standard of care). Due to the low pH of the dexrazoxane solution that would jeopardize the blinding no placebo is used. Cardiac function will be screened with echocardiography prior to the initiation of chemotherapy and followed-up at 4- and 12-months post randomization. The primary end point of the study will be the incidence of AICD, defined as a left ventricular ejection fraction (LVEF) decline of ≥10 percentage points from baseline and below 50% (normal reference value for two-dimensional (2D) echocardiography). The secondary endpoint will be the percentage of patients with complete metabolic remission (CMR) after R-CHOP chemotherapy, to reassure that dexrazoxane does not influence the antineoplastic efficacy of doxorubicin. To declare ANTICIPATE successful, the trial must show both the superiority of addition of dexrazoxane on the primary endpoint and non-inferiority on the secondary endpoint. Deep-phenotyping of patient- and treatment-related factors will be performed to evaluate their prognostic value.
The invention provides ginseng glycoprotein and a preparation method and application thereof. The weight average molecular weight of the ginseng glycoprotein is 9000-. The invention proves that the ginseng glycoprotein has the function of treating oligospermia through pharmacodynamic experiments. The invention utilizes FITC to carry out fluorescence labeling on ginseng glycoprotein and utilizes the mouse integral imaging technology to observe the tissue distribution and the targeting efficiency of the drug. The experimental result shows that the ginseng glycoprotein has the testis tissue targeting tendency. The ginseng glycoprotein provided by the invention has the advantages of simple preparation process, high relative yield, reduction of the manufacturing cost and good research and application values.
Snakebite envenoming is a neglected tropical disease that causes substantial mortality and morbidity globally. The venom of African spitting cobras often causes permanent injury via tissue-destructive dermonecrosis at the bite site, which is ineffectively treated by current antivenoms. To address this therapeutic gap, we identified the etiological venom toxins in Naja nigricollis venom responsible for causing local dermonecrosis. While cytotoxic three-finger toxins were primarily responsible for causing spitting cobra cytotoxicity in cultured keratinocytes, their potentiation by phospholipases A2 toxins was essential to cause dermonecrosis in vivo. This evidence of probable toxin synergism suggests that a single toxin-family inhibiting drug could prevent local envenoming. We show that local injection with the repurposed phospholipase A2-inhibiting drug varespladib significantly prevents local tissue damage caused by several spitting cobra venoms in murine models of envenoming. Our findings therefore provide a therapeutic strategy that may effectively prevent life-changing morbidity caused by snakebite in rural Africa.
The invention discloses medicinal liquor for treating shrinking deformation of limb muscles. The medicinal liquor for treating shrinking deformation of the limb muscles comprises caulis clematidis armandii, ser. ornithophyllae ku, monkshood, radix aconite, radix clematidis, camphorwood barks, pine barks, carthamus tinctorius, roots of indian stringbush, wild buckwheat roots, polygonum cuspidatum, radix notoginseng, asarum heterotropoide, arabian jasmine flowers, rhizoma acori graminei, common vladimiria roots, Chinese azalea flowers, semen strychni and short-tube lycoris. By the medicinal liquor for treating shrinking deformation of the limb muscles, the medicine can directly permeate in a skin wound quickly and can be absorbed, and the purpose of treating diseases is achieved; after the medicinal liquor is wiped on the skin wound, an effect of eliminating and releasing toxicant on a local lesion is achieved, and pain of a patient on the lesion is reduced; skin wounds caused by acupuncture and moxibustion are strongly stimulated, and after acupuncture and moxibustion are applied together with the externally used medicinal liquor, an effect of thermotherapy and activation of blood is achieved. Moreover, the medicinal liquor can be used for targeted therapy on a focus portion with poor local peripheral circulation. The medicinal liquor for treating shrinking deformation of the limb muscles does not have a rebound effect when used for treating patients suffering from limb shrinking deformation. The curative effect of the medicinal liquor is higher than that of recovery massaging.
TENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
Binge eating (BE) is consuming large amounts of food in a short time, while experiencing loss of control over eating behavior. BE can be hereditary, and juvenile stress (JS) may contribute to its onset. We examined the impact of JS on BE-like behavior, in an animal model of intergenerational BE. Twenty-four female Wistar rats received 2-h access to palatable food (PF) three or five times a week (3 TW or 5 TW) for 4 weeks, followed by the open field test (OFT). At postnatal day (PND)27-29, female offspring either underwent JS (O-JSC) or not (O-CC). At PND51-53, offspring's stress levels were assessed behaviorally. At PND70-85, offspring received 2-h access to PF three times a week to assess their BE-like tendency. Hair samples were collected afterwards. Compared to 5 TW, 3 TW had a greater binge size. In the elevated plus maze and dark\light box, in O-JSC, offspring of 3 TW (O-3TW) spent less time in the open arms and lit area compared to O-5TW. O-3TW consumed more PF than O-5TW. O-JSC consumed more than O-CC. O-3TW-JSC had higher hair CORT levels than O-3TW-CC and O-5TW-JSC. This study highlights the interplay between maternal and offspring experiences, allowing for the study of underlying mechanisms.
NEW MATERIAL:A compound of formula I (A, B are O, S; X is H or halogen; but at least one of A and B is S). EXAMPLE:2-Thio-1-aminouracil. USE:A central nerve inhibitor or antianxiety agent. Useful for depressing tension, anxietas, agrypnia, etc., caused by stress, etc. PREPARATION:An aminouracil compound of formula II is reacted with a sulfiding agent (e.g. phosphorus pentasulfide) in a solvent such as 1,4-dioxane at 20 deg.C to the refluxing temperature of the solvent for 30 min to 5 hr to prepare the compound of formula I. The sulfiding agent is employed in an amount of 0.5-5 times moles per 1 mole of the compound of formula II.
In this cross-sectional study, participants answered a DEPS-R and EDE-Q questionnaire during a regularly scheduled medical visit after obtaining written informed consent. All participants had established that patients with T1D were treated with multiple daily insulin or insulin pump therapy. Height was measured using a stadiometer to the nearest 0.1 cm in all participants. Weight was measured unclothed to the nearest 0.1 kg using a calibrated balance scale. Body Mass Index (BMI) was calculated by using the weight (kg)/height (m²) equation. Clinical data including HbA1c, T1D onset, birth date, and treatment model etc. was conducted as part of a standard clinical assessment. HbA1c was measured with ion-exchange high-performance liquid chromatography (Bio-rad Variant ll Turbo, Japan).